Literature DB >> 32483602

RE: Oral Leukoplakia and Risk of Progression to Oral Cancer: A Population-Based Cohort Study.

Burkhard H Brandt1, Natalia Bednarz-Knoll2, Johannes Kleinheinz3, Andre Franke4, Thomas Fillies5.   

Abstract

Entities:  

Year:  2020        PMID: 32483602      PMCID: PMC7492755          DOI: 10.1093/jnci/djaa074

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  7 in total

1.  Aberrations of erbB-1 and erbB-2 oncogenes in non-dysplastic leukoplakias of the oral cavity.

Authors:  R Werkmeister; B Brandt; U Joos
Journal:  Br J Oral Maxillofac Surg       Date:  1999-12       Impact factor: 1.651

2.  Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer.

Authors:  Mohammed Taoudi Benchekroun; Pierre Saintigny; Sufi M Thomas; Adel K El-Naggar; Vassiliki Papadimitrakopoulou; Hening Ren; Wenhua Lang; You-Hong Fan; Jianhua Huang; Lei Feng; J Jack Lee; Edward S Kim; Waun Ki Hong; Faye M Johnson; Jennifer R Grandis; Li Mao
Journal:  Cancer Prev Res (Phila)       Date:  2010-06-22

Review 3.  Mechanisms of egfr gene transcription modulation: relationship to cancer risk and therapy response.

Authors:  Burkhard Brandt; Sönke Meyer-Staeckling; Hartmut Schmidt; Konstantin Agelopoulos; Horst Buerger
Journal:  Clin Cancer Res       Date:  2006-12-15       Impact factor: 12.531

4.  Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer.

Authors:  J R Grandis; D J Tweardy
Journal:  Cancer Res       Date:  1993-08-01       Impact factor: 12.701

5.  Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.

Authors:  Charles M Rudin; Wanqing Liu; Apurva Desai; Theodore Karrison; Xuemin Jiang; Linda Janisch; Soma Das; Jacqueline Ramirez; Balasubramanian Poonkuzhali; Erin Schuetz; Donna Lee Fackenthal; Peixian Chen; Deborah K Armstrong; Julie R Brahmer; Gini F Fleming; Everett E Vokes; Michael A Carducci; Mark J Ratain
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

6.  Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.

Authors:  William N William; Vassiliki Papadimitrakopoulou; J Jack Lee; Li Mao; Ezra E W Cohen; Heather Y Lin; Ann M Gillenwater; Jack W Martin; Mark W Lingen; Jay O Boyle; Dong M Shin; Nadarajah Vigneswaran; Nancy Shinn; John V Heymach; Ignacio I Wistuba; Ximing Tang; Edward S Kim; Pierre Saintigny; Elizabeth A Blair; Timothy Meiller; J Silvio Gutkind; Jeffrey Myers; Adel El-Naggar; Scott M Lippman
Journal:  JAMA Oncol       Date:  2016-02       Impact factor: 31.777

7.  Oral Leukoplakia and Risk of Progression to Oral Cancer: A Population-Based Cohort Study.

Authors:  Anil K Chaturvedi; Natalia Udaltsova; Eric A Engels; Jed A Katzel; Elizabeth L Yanik; Hormuzd A Katki; Mark W Lingen; Michael J Silverberg
Journal:  J Natl Cancer Inst       Date:  2020-10-01       Impact factor: 13.506

  7 in total
  1 in total

1.  Response to Brandt, Bednarz-Knoll, Kleinheinz et al.

Authors:  Anil K Chaturvedi; Natalia Udaltsova; Eric A Engels; Jed A Katzel; Elizabeth L Yanik; Hormuzd A Katki; Mark W Lingen; Michael J Silverberg
Journal:  J Natl Cancer Inst       Date:  2020-09-01       Impact factor: 13.506

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.